---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical presentation - signs and symptoms. Topics: Visual symptoms: blurred vision, visual field defect, and photopsia before diagnosis of the primary tumor; Visual symptoms by tumor location; Ocular signs: retinal detachment and secondary angle-closure glaucoma; Asymptomatic primary tumors detected on routine examination; 6 further topics. 10 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Visual symptoms: blurred vision, visual field defect, and photopsia before diagnosis of the primary tumor

| Symptom before diagnosis, 159 Finnish patients | Patients, n | Patients, % |
| --- | --- | --- |
| Blurred vision | “78” | “49” |
| Visual field defect | “51” | “32” |
| Photopsia | “29” | “18” |
| Irritation and pain | “26” | “16” |
| Metamorphopsia | “10” | “6” |
| Floaters | “9” | “6” |
| Asymptomatic | “20” | “13” |

Source: [Eskelin et al. (2002)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1771030/)

<a id="topic-2.2.1.6-2"></a>

### Visual symptoms by tumor location

> “Most uveal melanomas are initially completely asymptomatic. As the tumor enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma).”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.6-3"></a>

### Ocular signs: retinal detachment and secondary angle-closure glaucoma

> “Serous detachment of the retina may occur. If extensive detachment occurs, secondary angle-closure glaucoma occasionally develops.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.6-4"></a>

### Asymptomatic primary tumors detected on routine examination

> “Although UM patients typically present with symptoms including blurred vision, visual field defect, metamorphopsia, or photopsia, 30% patients may be asymptomatic and upon routine eye examination, they are detected incidentally.”

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

> “On referral, 30.2% of patients were asymptomatic.”

Source: [Damato et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22503229/)

<a id="topic-2.2.1.6-5"></a>

### Ocular pain and vision loss in a case series of synchronous primary and metastatic disease

> “Seventeen patients (81%) had ophthalmic symptoms at diagnosis.”
> “Common symptoms were loss of vision (n=12), myodesopsia (n=4), photopsia (n=3) and eye pain (n=5).”

Source: [Steckler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8901542/)

<a id="topic-2.2.1.6-6"></a>

### Hepatic and constitutional symptoms: abdominal pain, anorexia, weight loss, and nausea at detection of metastasis

> “Among the symptomatic group, metastasis was diagnosed in 259 patients (74.2%) after the onset of symptoms, such as anorexia or abdominal pain.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

> “Ten patients were diagnosed after presenting with symptoms (weight loss, abdominal pain, nausea, back pain).”

Source: [Xu et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6751472/)

<a id="topic-2.2.1.6-7"></a>

### Asymptomatic metastatic disease at detection

> “Of all the patients, 59% (95% CI, 43-73) were asymptomatic, and 80% (95% CI, 66-91) had only hepatic metastases.”

Source: [Eskelin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10091801/)

<a id="topic-2.2.1.6-8"></a>

### Physical signs of metastasis: hepatomegaly, lymphadenopathy, and subcutaneous nodules

> “In 1985, the Collaborative Ocular Melanoma Study (COMS) employed a combination of physical examination for hepatomegaly, enlarged lymph nodes and subcutaneous nodules as well as ancillary chest X-rays and liver function tests.”

Source: [Garg et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8961763/)

<a id="topic-2.2.1.6-9"></a>

### Laboratory signs: elevated lactate dehydrogenase and alkaline phosphatase at diagnosis of metastasis

> “Lactate dehydrogenase level (LDH) was elevated in 85 (48.6%) patients (Table 1).”

Source: [Jochems et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6678641/)

> “Serum or plasma alkaline phosphatase exceeded the upper normal limit (UNL) in 26% of 193 patients with available data.”

Source: [Rantala et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8081447/)

<a id="topic-2.2.1.6-10"></a>

### Neurological symptoms: brain metastases

> “116/1,845 (6.3%) mUM patients were identified with BM.”
> “Brain imaging was obtained only upon onset of neurological symptoms in most cases of identified brain metastases and not for asymptomatic surveillance.”

Source: [Wei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9540230/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
